MariMed Inc. (MRMD) reported a robust revenue increase in the second quarter of 2024, with a notable 11% year-over-year growth, totaling $40.4 million. The company's success was marked by a strong performance in its wholesale segment across core markets, and significant sequential growth in retail sales.
MariMed continues to focus on improving margins, particularly in Illinois, and is optimistic about generating increased cash flow moving forward. The quarter also saw the company achieving significant milestones, including the commencement of adult-use sales in Massachusetts and expansion efforts in Maryland and Missouri.
Key Takeaways
- MariMed's Q2 revenue hit $40.4 million, an 11% increase from the previous year.
- Strong growth was driven by wholesale operations and robust retail sales.
- The company is maintaining its financial targets for 2024, anticipating further growth in the latter half of the year.
- Strategic milestones achieved include the transfer and acquisition of dispensary licenses and the initiation of adult-use sales in Massachusetts.
- MariMed is focusing on expanding market coverage and shelf presence across all product categories.
- The CEO highlighted the company's conservative balance sheet and access to capital for future acquisitions.
- Management expressed frustration over the undervaluation of cannabis stocks despite strong financial performance.
Company Outlook
- MariMed aims to maintain its financial targets for 2024.
- Plans to expand into additional high-growth categories and increase market coverage.
- The company is preparing to enter the Missouri market pending regulatory approval.
Bearish Highlights
- The CEO voiced concerns over the undervaluation of cannabis stocks in the market.
- Management urged investors to recognize the undervaluation issue in spite of the company's financial progress.
Bullish Highlights
- Revenue growth is expected to continue in the second half of 2024.
- The company has a conservative balance sheet and is strategically positioned for future acquisitions.
- New assets are performing well, with positive brand performance in Massachusetts.
Misses
- There were no specific financial misses reported in the earnings call.
Q&A Highlights
- Discussion on the performance of newly opened assets and expected margin improvements.
- Upcoming store openings in Maryland and Missouri were addressed.
- The CEO's excitement about the new CFO joining the company.
MariMed's second quarter performance in 2024 has been marked by significant revenue growth and strategic expansions, reflecting the company's strong position in the cannabis industry. Despite facing challenges such as the undervaluation of cannabis stocks, MariMed's leadership remains committed to building a profitable business and capitalizing on future opportunities for growth. With a focus on increasing market presence and expanding into new territories, MariMed is poised to continue its upward trajectory in the latter half of the year.
InvestingPro Insights
MariMed Inc. (MRMD) has demonstrated resilience with its robust revenue growth in Q2 2024, but the picture painted by the latest InvestingPro data and insights suggests a nuanced financial landscape. The company's market capitalization stands at $66.56 million, reflecting its position within the cannabis market. Despite a challenging environment, MariMed's revenue has shown an admirable year-over-year increase of 10.97%, totaling $156.07 million for the last twelve months as of Q2 2024.
A significant highlight from the InvestingPro Tips is the anticipated net income growth this year, which aligns with the company's optimism about its financial targets for 2024. This growth may be fueled by the strategic expansions in Massachusetts, Maryland, and Missouri, as well as the company's efforts to improve margins and cash flow. Additionally, analysts predict MariMed will achieve profitability this year, which could be a pivotal turning point for the company, especially considering it has not been profitable over the last twelve months.
However, it's important to note that MariMed operates with a significant debt burden, and the stock has experienced a substantial decline over the last six months, with a 47.54% drop in price total return. This could be a point of concern for investors, given that the company does not pay dividends, potentially limiting the immediate financial incentives for shareholders.
For those interested in a deeper dive into MariMed's financial health and future prospects, there are more InvestingPro Tips available at https://www.investing.com/pro/MRMD, offering a comprehensive analysis that could inform investment decisions.
Full transcript - Marimed Inc (MRMD) Q2 2024:
Operator: Good morning. My name is Jeanne and I will be your conference operator today. At this time, I would like to welcome everyone to the MariMed Second Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. I will now turn the line over to Mr. Steve West, Vice President of Investor Relations to begin the conference. Please go ahead.
Steve West: Good morning, everyone, and welcome to MariMed's second quarter 2024 earnings call. Joining me today are Jon Levine, our Chief Executive Officer; and Ryan Crandall, our Chief Revenue Officer. This call will be archived on our Investor Relations website and contains forward-looking statements. Actual events or results may differ materially from these forward-looking statements and are subject to various risks and uncertainties. A discussion of some of these risks is in the Risk Factors section of our 10-K, available on our website. Any forward-looking statements reflect management's expectations as of today, and we assume no obligation to update them unless required by law. Additionally, we will refer to certain non-GAAP financial measures, which are reconciled in our earnings release. Finally, our third quarter 2024 earnings release is tentatively scheduled to be issued after the markets close on November 06, and our Analyst Call is tentatively scheduled to be held the morning of November 07 at 8:00 a.m. I will now turn the call over to Jon.
Jon Levine: Thank you, Steve, and good morning everyone. We have a lot to discuss, so let's dive in. Most importantly, I'm pleased to report we remain on track to deliver our 2024 financial targets. Revenue growth was very strong both year-over-year and sequentially. Our wholesale business had another tremendous quarter in all of our core markets. Retail sales showed strong sequential growth and we had our 7th consecutive quarter of double-digit transaction growth on a year-over-year basis. Now let's talk about margins. MariMed remains in the growth phase of our life cycle. Our long-term investments will pay off as we continue to scale in Maryland and Illinois, and we are already seeing margin improvement in Illinois, where our retail gross margins improved about 145 basis points versus last year and 250 basis points versus last quarter. In the short-term, though, these investments are a drag on margin and cash flow. This was compounded in the second quarter when consumer weaknesses persisted in all retail sectors, including cannabis. Despite these headwinds, we were able to grow revenue by investing in creative marketing programs and extending store hours among other things. I have said it before, but it bears repeating, we are right where other MSOs were a few years ago during their growth cycles. It wasn't until they completed their investment and their assets began to mature that they began reporting margin expansion and increased cash flow. I am certain that day is coming from MariMed, and it will come without the significant debt our peers carry on their balance sheets. Now let me review some of the key achievements since the end of the first quarter. In Illinois, we announced the transfer of the dispensary license in Casey, which allowed us to roll up their financials. We are finally on the verge of receiving state approval to start cultivation at our facility in Mt. Vernon. This will allow us to launch our Nature’s Heritage and InHouse flower brand into the state. We expect to begin selling our flower in the first quarter of 2025. In Maryland, we closed on the acquisition of our second adult dispensary, which we expect to open soon. Also in Maryland, we began cultivation operations in our newly expanded facility in Hagerstown. As of today, we have five of the nine grow rooms already online. The plan is to bring another room online each week until they are all filled with beautiful new plants. This will effectively double our flower yield, making us one of the largest flower producers in the state. We expect our first harvest to be on shelves in Q4. In Massachusetts, we announced the commencement of adult-use sales at our Quincy dispensary in July. In Ohio, we'll commence adult sales as soon as we receive final regulatory approval. And finally, in Missouri, we are close to receiving final approval to begin operations for our processing kitchen. So, to summarize, our revenue continues to grow. We're tracking with guidance and we've got some additional new assets coming online soon. With that, let me turn over to Ryan for his sales and marketing discussions.
Ryan Crandall: Thanks Jon, and good morning, everyone. Our big story for the quarter was our sequential revenue growth in both wholesale and retail. And I could not be prouder of the teams that made it happen. Our wholesale did extremely well, growing 9% sequentially to $15.9 million. Additionally, this marked the 8th consecutive quarter of at least 30% year-over-year growth in wholesale. And I'm pleased to say that we reported sequential growth in all three of our markets. The standout was Illinois, where we more than doubled our sales versus the first quarter, increased dispensary distribution and velocity were the main drivers with our products now available in over 140 dispensaries. We have been in the market long enough to see that consumers are trying our products and coming back for more. We knew the return of Betty's Eddies to Illinois would be a win, but Bubby's, Vibations and InHouse are selling really well too. Massachusetts and Maryland also continue to grow. In Massachusetts, our wholesale business continues to take market share, reporting its 7th consecutive quarter of year-over-year growth. The power of our branded edible products continues to lead to increased unit and dollar sales. In fact, according to BDSA, Betty's Eddies just became the number one edible in the state of Massachusetts. Maryland reported double digit year-over-year growth for the 6th consecutive quarter, and with the recent commencement of operations in our newly expanded cultivation facility, we expect the business will continue to grow. Moving to retail sales, our revenue grew 6% sequentially to $23.6 million. The investments in training, expanding store hours, leveraging our strong loyalty program, and improving accessibility all helped drive sequential transaction growth of 8% through our owns network of stores. The key to driving sales growth in both wholesale and retail channels is having excellent brands with consistent innovation around existing and potentially new products. The power of our brand speaks for itself. I mentioned earlier that Betty's is now number one in Massachusetts. While Betty's is number two in Maryland and while I'm on the subject of market share rankings, let's talk about our other edibles. Bubby's is the dominant number one baked good brand in both Massachusetts and Maryland, and Vibations is the number two beverage brand in Maryland. Our award winning branded edibles together with Nature's Heritage flower has MariMed on the podium as market leader in two of the larger cannabis markets in the country, and we have Illinois in our crosshairs with the intent to replicate our successes on the east coast. Before closing, I want to say how excited I am that we are tracking ahead of the revenue guidance and we still have upside opportunities for the second half of the year that could accelerate revenue growth even further, so stay tuned. With that, I turn the call over to Steve for his financial review.
Steve West: Thank you, Ryan. Our second quarter revenue was $40.4 million, which increased 11% year-over-year, driven by robust growth in our wholesale business, partially offset by lower retail and other revenue. Our second quarter non-GAAP adjusted gross margin was 42.9%, which declined versus our Q1 2024 adjusted gross margin of 43.8%. This was primarily due to higher input costs, labor and the ramp up costs associated with our new assets that Jon spoke about earlier. Our reported adjusted EBITDA of $4.4 million during the quarter was down compared to our Q2 2023 adjusted EBITDA of $6.3 million. The year-over-year change in adjusted EBITDA was due to lower gross margin and higher operating expenses associated with our growth initiatives. Turning to the balance sheet and cash flow, we ended the second quarter with $10.2 million of cash and cash equivalents, a decline versus our 2023 year-end cash balance of $14.6 million. This was due to increased cash expenditures on acquisitions and inventory. As discussed last quarter, our inventory increased due to ramping up our new asset. As a percentage of sales, our inventory was 0.77x the same as we reported for the first quarter. Our working capital, which continues to be a strength for the company, was $12.4 million. For the year-to-date we reported cash flow from operations of $6.4 million as compared to operating cash burn of $3.2 million in the same period last year. Additionally, we spent $8.3 million on CapEx year-to-date compared to $8.8 million for the same period last year. Now moving to our 2024 outlook as reported last night, we are maintaining our full year 2024 financial targets of 5% to 7% revenue growth, 0% to 2% adjusted EBITDA growth, and approximately $10 million in CapEx. That concludes our financial review. I will now turn the call back over to Jon for his concluding remarks.
Jon Levine: Thank you, Steve. We have remained hyper focused on implementing our strategic growth plan and I'm confident about the path we're taking towards our future. Looking at the remainder of 2024, as Ryan said earlier, we still have initiatives we are executing to further accelerate our revenue growth and future margin expansion. These include adult-use sales in Quincy, Mass and Tiffin, Ohio dispensary opening our second adult-use dispensary in Maryland and commencing wholesale operations and reserve. And remember, we have a second dispensary license in Ohio that will build out in the future. Looking further out, we're excited about Delaware, which recently passage of adult-use legislation our Delaware partner First State Compassion should commence adult sales this fall. We believe we will be able to complete the key pillar of our strategic growth plan and integrate FSC and its financial results into MariMed sometime in 2025. That would be huge as First State as a number one market share in Delaware. I now want to talk about the elephant in the room, our stock price. There are many adjectives to describe how I feel, but most of them are inappropriate for this call. You could say I'm frustrated or disappointed, but the best and cleanest word I can describe how I feel is angry. I can't believe how inefficient the market is with respect to valuing cannabis stocks, including ours. The Verano cannabis deal announced last week is a great example. Verano is acquiring Virginia and Arizona assets from the cannabis for $105 million in total consideration. Do you realize that on the morning of that announcement, the cannabis market cap was only $90 million? In other words, they'll receive more than their market cap in total consideration for just their Arizona and half of their Virginia businesses. That is a great example how cannabis stocks don't properly reflect the underlying value of the company's assets. It's an issue affecting nearly every cannabis company, including ours. So since we can't control the stock market, we will continue to keep our nose to the grindstone and focus on building a strong, profitable cannabis company. We still have one of the most conservative balance sheets in the industry, and we have access to cheap capital through our Needham Bank relationship. This will allow us to make future acquisitions that make strategic and economic sense. To that point, we have robust pipeline of targets that we're analyzing. All the ingredients are in place to fuel our long-term growth and assuming the market starts acting with some sense of normalcy our performance should finally be rewarded with higher stock price. In short, I'm bullish as ever about the future of our company in the cannabis industry. Hearing that, I know some will still ask, why don't you institute a stock repurchase program? The Executive Team and the Board of Directors believe investing in long-term revenue and profitable growth initiatives is the best use of our capital at this point of time. Before closing, I’d like to say I am so excited about our new Chief Financial Officer, Mario Pinho, joining the company. Mario has been working with us behind the scenes for the past month and will officially take the reins of CFO tomorrow. He is a great leader with extensive and valuable experience to help accelerate our growth. More importantly, Mario is a great guy who fits perfectly into our culture. I’m excited for you to get to know him. I’d like to personally thank all our long-term investors for their vigilance in challenging us to do better and for your patience as we prove out our growth plan. And finally, to our great MariMed team. Thank you. You’re the best in the business. Operator, you may open the line for questions.
Operator: Thank you, ladies and gentlemen, we will now begin the question-and-answer session. [Operator Instructions] Your first question is from Andrew Semple from Ventum Financial. Please ask your question.
Andrew Semple: Hi there. Good morning. First of all, congrats on the number of operational achievements across many of your key markets in recent weeks. My first question here would just be on the newly opened assets in Quincy and the Maryland cultivation. How is that Quincy store performed during your first few weeks of operations there? Is that living up to your expectations? And second part of that would just be on the new grow rooms at the Maryland facility. Are those also performing up to the typical MariMed standard?
Jon Levine: Good morning, Andrew. Thank you so much for coming on. Great questions. I am happy that you’re asking about our newly opened assets. The grow rooms I’ll start with in Hagerstown, they look so good. The flowers really take on strongly. The rooms came out great. The environments are some of the best that we’ve built out, and we’re very excited that we’re on schedule opening up each of those grow rooms each week. That will have a full cycle at the end of the filling of the rest of the rooms. And in Quincy, the store opened up. It was a little slow at the beginning, but we’ve seen increase every day in every week and we’re going to hopefully continue to see that. We’re very bullish on it, and we’re excited that we’re finally opened that Quincy asset with adult use. I think as people get to know that we’re there, that we’ll see even more improvement as we go forward.
Andrew Semple: Great, that’s helpful. Second question would just be the commentary on the margins. Understand that we should be expecting temporary – temporary drag here as MariMed continues to invest in growth. Though, would be helpful to have some sort of sense on where we are in that growth phase today, maybe what the timing of when you would expect margins beginning to recover. So my question there would be, will we see some margin expansion in the second half, or is that more of the 2025 story?
Jon Levine: Andrew, it’s John again. Great question tonight. Thank you for it. The margins will start to improve as our assets come online. Hagerstown was one of those assets that we’ve been front loading and carrying. It will be about another three months before we start seeing revenue ramp up to offset those and create additional margins. But we’re also seeing improved margins in Illinois with the opening of our production facility. Our production facility is still ramping up. We’re not even at 100% of our full production there. And our retail sales, as I said earlier, are already showing the improvements of margin as we’re able to sell our product there and improve our margins. And as everybody has been reporting, this has been a very tough time with the economic factors, and we’re all seeing decreases, but we’re seeing increases in footprint of who’s coming in, and we’re hopeful to continue to see those margins in three and four. So we’re very bullish on trying to increase our margins in the latter half of the year.
Andrew Semple: Great. And maybe one more quick one, if I may, just to go back to Massachusetts, which is an important market for MariMed, maybe just a quick update on how wholesale dynamics have been faring in that state, both from a pricing and demand standpoint.
Ryan Crandall: Sure. Andrew, this is Ryan. We are faring very, very well in Massachusetts, which is a very difficult market. I would say our brands and our products are leading the way. We’re continuing to innovate the market leading brands in the market. So, we’re not resting on our laurels. We are continuing to throw the ball down the field. And customers and the folks buying our products, it’s resonating with them. And that’s showing quarter after quarter. So we’re very proud of that. Our sales people, our ops teams, we’re continuing to create great products and sell great products every day, and we’re continuing to refine that process. So I am very bullish on the team and what we’re doing in the Mass market, and I think Maryland as well as Illinois wholesale will follow that same trend.
Andrew Semple: That’s great. That’s helpful. Thanks for taking my questions. I will get back into queue.
Operator: Thank you. Your next question is from Pablo Zuanic from Zuanic. Please ask your question.
Pablo Zuanic: Good morning, everyone. And yes, congratulations on the quarter. Look, maybe this one is for Steve or Ryan. Just let’s try to unpack the guidance a little bit. It seems to me that some things are coming in earlier than expected and we’re not factoring guidance, right. I think Quincy rack, the second Maryland store, I believe the production expansion in Maryland and the Ohio store rack were factored. But just a reminder, what was not included in guidance. And along the same lines, is there anything that’s behind schedule? I think you talked about Illinois production flower by early 2025. I believe that was supposed to be second half, 2024. Just – if you can just remind us and unpack a little bit the pieces of the guidance. Thank you.
Ryan Crandall: Good morning, Pablo. Thank you for joining us. And great questions. And I am happy that you asked it that we can be a little bit more specific. Our Hagerstown Facility was in our original guidance, and we were actually on time with that. So that will be part of the ramp up that was in the guidance. Quincy, you are correct. We came on with Quincy after the quarter end and with the tough markets, we were just being cautious not to increase any of our guidance at this time until Q3, when we have a better handle of how Quincy is going to do in effect, so that we’re not going to have to make any adjustments. We are late with our Illinois Hagerstown – sorry, Mount Vernon Grove of flower. And that will not be coming in until Q1, probably of 2025. That delay was due to many reasons, but we are still very bullish on our guidance because of the fact that we are seeing increases of other items like the Hagerstown and Quincy that will be coming in. But we will also look at the overall that the retail in Illinois is also increasing, like I said earlier, those margins will be able to hit. So we’re still very bullish on our guidance at this time.
Pablo Zuanic: That’s right. And you are also tracking ahead of it. And again, staying on the same question, the second story in Maryland, I don’t think it was part of guidance. When do you expect to open – to start generating revenue from that second story, or that’s not confirmed yet, the exact date?
Ryan Crandall: Well, we don’t have the exact date, but we are hoping for a final inspection sometime next week and being able to open in the next few weeks. Again, that’s all just guess work right now. But we are very excited about the fact that we’re really close to being able to open that second store. That was not part of our guidance. Again, that will be a Q3 adjustment when we get those stores open.
Pablo Zuanic: Right. Okay, thank you. Look, just moving on to edibles. I mean, obviously, great performance there in, as you mentioned, Massachusetts, Maryland, how far can that go? And what I mean by that, in the case of flower, we think of flower as a more segment – more fragmented market. If we look at other markets, California edibles tend to be a quite concentrated category. So, yes, you’re number one, number two. But compared to other states and the strength of your brand, that could have a lot of room to grow in terms of market share. So I don’t know if you can give any thoughts along those lines, specifically on edibles. What is reasonable – I am not asking you to guide on market share, but again, some of these edible brands have 20% plus share in some states. Here, you’re number one, I think, with 8%, 9%. So you would have a lot of room to grow there in terms of share or that’s just wishful thinking. Thanks.
Jon Levine: Pablo, thank you for the question. Yes, I think you are saying exactly what we’re thinking. We think the ceiling for our brands is high. And although we are at the top of several of these categories, we believe the ceiling on the categories is much higher [indiscernible] currently fit. So that’s why we continue to innovate, that’s why we continue to drive our brands across all the dispensaries. We’re not looking to get a single product or a single SKU in a store. We’re looking for full coverage. We want full shelf space for the category. And we look to build that out everywhere, so we’re not sitting on our hands. We’re doing that in all the categories we play today. You’re going to see us add additional categories that are going to make sense, that are going to have high growth potential. So I think [indiscernible] very exciting in the future for us.
Pablo Zuanic: And then just one last in the case of Massachusetts, I know the question came up before, but that’s a state that a lot of your peers are complaining of price pressures, more stores, diluting revenue per store, generally seen as a tough market from an economics perspective. But here you are gaining market share and doing quite well. I don’t know if you want to give more color in terms of what’s behind that.
Ryan Crandall: Sure Pablo. I mean, I think it’s a testament to the people and the team, along with the brands and the products. So I think it’s a recipe for success. But the folks that are doing the work, are doing great work, whether that’s in the production facility, creating the products, the folks out there selling every day that are dealing with the pricing pressure, the marketing folks that are developing these brands and products and paying attention to consumer need. So it’s a company [indiscernible], and we’re all very proud of it. But certainly the sales folks are the tip of the spear.
Pablo Zuanic: And one last one regarding Missouri, obviously, because of your performance in edibles in other states, I think, it’s reasonable to have high hopes of how well you could do in Missouri. I mean, is that done one thing is a transaction another thing is approval. What’s the line of sight in terms of where you can start actually selling there or not clear also?
Jon Levine: Mario right, we’re just – not Mario, sorry. Pablo we’re just waiting for the approval to open up the managed service agreement in Missouri, which we should have in the next week or two, and then we will be able to get our brands into Missouri sometime in the next quarter. So we’re very excited about Missouri. We’re not too far off, but we will not be able to, at first, get the 100% revenue, but we’ll get the management revenue until the state approves the final transfer.
Pablo Zuanic: Right, okay. Thank you very much.
Operator: Thank you. [Operator Instructions] Your next question is from William McNarland from TDR Research. Please ask your question.
William McNarland: Hi, gentlemen. I know you touched on it a bit, but do you have any additional colors as to why you feel there is such an extreme disconnect between the stock price and the financial progress?
Jon Levine: Well, the stock price, as I said, I’m angry and it’s the nicest word I can use, I guess, today. I mean, when you look at the example I gave of the Verano cannabis deal, you are just looking that they just sold off just two assets of all their assets, and it was for greater value than their market cap. That just shows you how undervalued all these cannabis companies are, including ours. If you look at our balance sheet, and our revenue, and our cash flow, we don’t deserve to be where we are with our market cap or our share value today. This market is just so undervalued for most cannabis companies that people need to start paying attention how bad this is.
William McNarland: Thank you.
Operator: Thank you. There are no further questions at this time. You may proceed.
Jon Levine: Thank you, everybody. I appreciate you joining our Q2 call. I hope you are here again for Q3. And I hope you understand the message that we’re sending out about not just our share price, but how good we’re doing. And thank you for your support. Have a good day.
Operator: Thank you. Ladies and gentlemen, the conference has now ended. Thank you all for joining. You may all disconnect your lines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.